Adenoma-derived antibody, Adnab-9 recognizes a membranebound glycoprotein in colonic tissue and effluent material from patients with colorectal neoplasia

Tobi, Martin; Maliakkal, Benedict; Zitron, Ian M.; Alousi, Majid; Goo, R. H.; Nochomovitz, Lucien E.; Luk, Gordon D.

doi:10.1016/0304-3835(92)90009-k

Cited by 17 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, more distal "adenoma" polyps tended to label with Adnab-9, reflecting the observed increased incidence of cancer in distal polyps. Therefore, compared to proximal lesions, distal "adenoma" labeling showed a stronger trend of labeling with Adnab-9 (a marker for the adenomacarcinoma sequence [14,16,18,30,36,37]) than with AD5, where the proportions were counterintuitive for a cancer risk marker. The fact that the concordance with AD5 was lower for proximal adenomas suggests that Adnab-9 is a stronger premalignant marker than AD5.…”

Section: Discussionmentioning

confidence: 94%

“…Adnab-9 binding has been shown to identify a subpopulation of cells in colonic adenomatous and normal mucosa from colons bearing CRC, but not carcinomatous tissue, some of which resemble Paneth cells (PC) (13)(14)(15)(16). The presence of Adnab-9 staining in nonneoplastic colonic epithelium has been shown to be associated with an increased risk for development of colorectal cancer (13)(14)(15)(16)(17). In addition, Adnab-9 staining has a positive correlation with multiplicity and recurrence of colonic polyps and may be a predictor of future development of dysplastic polyps with recognized malignant potential in these patients (18).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Differential Labeling by Monoclonal Antibodies Adnab-9 and Anti-?-Defensin 5 Based on the Distribution and Adenomatous Tissue Content of Colonic Polyps

et al. 2005

View full text Add to dashboard Cite

We sought a correlation between site and morphology of colonic polyps by labeling with neoplastic and general Paneth cell markers, monoclonal antibodies Adnab-9 and anti-alpha-defensin 5, respectively. Proportions labeled by Adnab-9 and anti-alpha-defensin 5 were, respectively, 42 and 85% for adenomas, 39 and 63% for early tubular adenomas, 41 and 44% for serrated, 34 and 20% for mixed, and 11 versus 2.7% for hyperplastic polyps. Compared with hyperplastic polyps, the proportion of other polyps labeled by Adnab-9 or anti-alpha-defensin 5 was higher but this difference was more significant for distal (P = 0.008 for Adnab-9 and P = 0.0001 for anti-alpha-defensin 5) than proximal (P = 0.645 and P = 0.154, respectively) polyps. While increased labeling of all proximal polyps compared to distal ones mirrored the colonic distribution of Paneth cells, distal adenomas tended to have a higher proportion labeled by Adnab-9, suggesting that Adnab-9 labels Paneth cells associated with increased neoplastic potential.

show abstract

Section: Discussionmentioning

confidence: 94%

mentioning

confidence: 99%

Differential Labeling by Monoclonal Antibodies Adnab-9 and Anti-?-Defensin 5 Based on the Distribution and Adenomatous Tissue Content of Colonic Polyps

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Reactivity with a monoclonal antibody generated from mice that had had been exposed to human adenoma tissue, known as ''Adnab-9,'' has been tested in WGLF [52,53] and found to react with a significantly higher percentage of patients at high risk for colorectal cancer (CRC) than controls [54]; however, it was also elevated in the feces of untreated celiac disease patients [55] and therefore may not be specific to cancer. Hemoglobin levels are also higher in WGLF of patients with CRC, diverticulosis, and IBS than in control patient which is not unexpected [56].…”

Section: Cancermentioning

confidence: 99%

Rectal Effluent as a Research Tool

2014

View full text Add to dashboard Cite

Studies of localized secretions are generally superior to those of blood because they contain higher concentrations of molecules specific to the organ of interest. A common method used to analyze localized secretions is lavage. The flow of fluid over the lining of a cavity picks up both cells and soluble factors, and the effluent can be collected for study. Gastrointestinal (GI) lavage is easily and noninvasively performed by the administration of gut lavage solutions such as those routinely given to patients prior to colonoscopy, with GI lavage fluid being the copious, watery rectal effluent subsequently induced. Residual effluent is currently suctioned from the colon and discarded during colonoscopy. With millions of routine colonoscopies performed per year, GI lavage fluid is a rich and largely untapped resource for basic and clinical research. Rectal effluent can also be easily collected in a toilet receptacle without need for a colonoscopy. Rectal effluent generated in this manner has been used to study diarrheal disease, mucosal immunology, inflammatory bowel disease, celiac disease, and cancer. It is often referred to as gut lavage, colon lavage, GI lavage, or whole gut lavage fluid, which makes it challenging to locate previous studies in the literature and there are currently no comprehensive reviews of its use as a research tool. This review attempts to fill this void by discussing previous applications of rectal effluent in research and the methods that have been developed for its collection, stabilization, and analysis.

show abstract

“…The antigen occurs early within the sequence but the exact interposition of the antigen within the sequence is not known [9,10]. Adnab-9 has been shown to identify an 87-kDa protein antigen found in the cytoplasm of cells in colonic adenomatous but not carcinomatous tissue, resembling Paneth cells, a source of growth factors in the gut [11].…”

Section: Introductionmentioning

confidence: 97%

“…Adnab-9 has been shown to identify an 87-kDa protein antigen found in the cytoplasm of cells in colonic adenomatous but not carcinomatous tissue, resembling Paneth cells, a source of growth factors in the gut [11]. The presence of Adnab-9 staining in nonneoplastic colonic epithelium has been associated with an increased risk for the development of bowel cancer [6,[8][9][10][11][12] and the diagnostic potential may be related to the presence of an Adnab-9-defined field effect [6]. Another recent study showed that positive labeling of severely dysplastic polyps by Adnab-9 is more significantly correlated with the presence of synchronous neoplastic lesions and neoplasia on subsequent colonoscopic follow-up than that of p53, a late-stage marker for the adenoma carcinoma sequence [13].…”

Section: Introductionmentioning

confidence: 99%

The Use of Early and Midpoint Adenoma-Carcinoma Sequence Biomarkers in Prediction of Neoplastic Progression in Patients with a History of Colorectal Neoplasia

et al. 2006

View full text Add to dashboard Cite

Since significant neoplasia after initial colonoscopy is low, we conducted this pilot study to compare the predictive role for colorectal neoplasia recurrence of anti-DCC with that of Adnab-9 binding to colonic effluent of high-risk patients. DCC and Adnab-9 effluent ELISA were performed at baseline colonoscopies. The results of follow-up colonoscopies were reviewed. To ensure specificity, immunohistochemistry and Western blot was performed with anti-DCC and for Adnab-9 where optimal fixation times were also evaluated. Mean follow-up was 2.6 years. Of 21 patients, 6 of 10 who progressed to CRN and 2 of 11 who did not had a positive Adnab-9 ELISA result (P=0.08). Despite an initial good correlation with Adnab-9 ELISA results in a smaller dataset, we were unable to obtain consistent subsequent DCC immunohistochemistry or Western blot data using antibody from two different sources. However, the original dataset of Adnab-9 results was reproducible on repetition of the ELISA with a larger set of samples that included this initial dataset and optimal fixation time was 20 min. We conclude that Adnab-9 appears to be a promising prognostic marker for neoplasia in the high-risk population. Industry standards need to be developed for DCC monoclonal antibodies that may have similar utility.

show abstract

Adenoma-derived antibody, Adnab-9 recognizes a membranebound glycoprotein in colonic tissue and effluent material from patients with colorectal neoplasia

Cited by 17 publications

References 9 publications

Differential Labeling by Monoclonal Antibodies Adnab-9 and Anti-?-Defensin 5 Based on the Distribution and Adenomatous Tissue Content of Colonic Polyps

Differential Labeling by Monoclonal Antibodies Adnab-9 and Anti-?-Defensin 5 Based on the Distribution and Adenomatous Tissue Content of Colonic Polyps

Rectal Effluent as a Research Tool

The Use of Early and Midpoint Adenoma-Carcinoma Sequence Biomarkers in Prediction of Neoplastic Progression in Patients with a History of Colorectal Neoplasia

Contact Info

Product

Resources

About